NASDAQ: AKTX
Akari Therapeutics PLC Stock Ownership - Who owns Akari Therapeutics?

Insider buying vs selling

Have Akari Therapeutics PLC insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Abizer GaslightwalaCEO2026-09-296,430$9.72
$62.50kBuy
Kameel D. FaragCFO;Interim2026-08-171,728$7.52
$12.99kBuy
Kameel D. FaragCFO;Interim2026-07-161,130$11.50
$13.00kBuy
Samir Rashmikant PatelDirector2026-07-071,209$8.00
$9.67kBuy
Kameel D. FaragInterim CFO2026-06-242,539$5.12
$13.00kBuy
Kameel D. FaragInterim CFO2026-06-247,353$3.74
$27.50kBuy
Kameel D. FaragInterim CFO2026-06-241,000$13.00
$13.00kBuy
Kameel D. FaragInterim CFO2026-06-243,725$3.49
$13.00kBuy
Kameel D. FaragInterim CFO2026-06-241,248$10.02
$12.50kBuy
Kameel D. FaragInterim CFO2026-06-241,395$9.32
$13.00kBuy

1 of 2

AKTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AKTX insiders and whales buy or sell their stock.

AKTX Shareholders

What type of owners hold Akari Therapeutics PLC stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Rachelle Suzanne Jacques0.65%1,018,027,792$8.88BInsider
Stuart Ungar0.46%722,345,600$6.30BInsider
Ray Prudo0.46%722,345,600$6.30BInsider
Rpc Pharma Ltd0.46%722,345,600$6.30BInsider
James Hill0.46%722,345,600$6.30BInsider
Hoyoung Huh0.14%223,719,311$1.95BInsider
Wendy F. Dicicco0.10%158,473,915$1.38BInsider
Sandip I. Patel0.08%121,026,008$1.06BInsider
Michael Grissinger0.01%20,000,000$174.40MInsider
Donald A. Williams0.01%20,000,000$174.40MInsider

1 of 3

AKTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NCNA0.00%0.01%
AKTX0.00%2.86%Net BuyingNet Buying
BDRX0.00%0.00%
SCNI0.00%4.50%
CDT0.00%100.00%Net Selling

Akari Therapeutics Stock Ownership FAQ

Who owns Akari Therapeutics?

Akari Therapeutics (NASDAQ: AKTX) is owned by 0.00% institutional shareholders, 2.86% Akari Therapeutics insiders, and 97.14% retail investors. Rachelle Suzanne Jacques is the largest individual Akari Therapeutics shareholder, owning 1.02B shares representing 0.65% of the company. Rachelle Suzanne Jacques's Akari Therapeutics shares are currently valued at $9.10B.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.